Sean C.S. Rivrud

Sean C.S. Rivrud

Auto-generated profile, based on publicly available information

Sean C.S. Rivrud

Department of Intensive Care, University Medical Center Groningen, Groningen, the Netherlands; Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2025 in EBioMedicine
Verified
Journal Article
Open access
WZWenbo Zhang
Wenbo Zhang
NNNam Nguyen-Hoang
Nam Nguyen-Hoang
SRSean C.S. Rivrud
Sean C.S. Rivrud
AZAnne-Fleur Zandbergen
Anne-Fleur Zandbergen
YYYalan Yan
Yalan Yan
Harold SniederHarold Snieder
Harold Snieder
Critical illness is complex, and genetic research holds the potential to uncover underlying disease mechanisms. However, existing research results have not been systematically summarized. This study aims to compile all genetic association studies in critically ill patients and assess their risks of bias. We systematically reviewed PubMed, EMBASE, and the Cochrane Library (PROSPERO protocol: CRD42021209744) and conducted a bias risk assessment of identified studies using a newly developed risk-of-bias assessment tool for genetic association studies. We compiled all significant single nucleotide polymorphisms (SNPs) from the studies identified in our systematic review and conducted a lookup in the results of two genome-wide association studies (GWASs) in critically ill patients. We identified a total of 61 studies that evaluated genetic variants with various traits in adult intensive care patients, encompassing a total of 126 genetic loci and focussing on six clustered critical care-related traits. Assessment of the risk of bias across these studies revealed that 97% of the studies demonstrated some concerns or high risk of bias and only two studies (3%, both GWAS), had an overall low risk of bias. Only two significantly associated SNPs emerged from the two studies assessed to have a low risk of bias. One SNP (rs4957796) in FER was associated with 28-day survival (p = 3.4 × 10-9) and mortality (p = 5.6 × 10-8), and rs9508032 in FLT1 was associated with respiratory failure (p = 5.2 × 10-8). Fifty-four significant associations were replicated in the candidate gene studies, but most had an overall high risk of bias. Only one association, of rs2569190 in CD14 with mortality, remained significant after multiple testing correction. Our systematic review underscored a deficiency in high-quality genetic research in critical care medicine. The detected gaps emphasize an urgent need for additional rigorous genetic association studies that are preferably genome-wide, to enhance our understanding of the underlying mechanisms of critical illness. Wenbo Zhang was financially supported by a grant from the China Scholarship Council (File no. 202006210041). Carlos Flores was funded by Instituto de Salud Carlos III (PI23/00980 and CB06/06/1088) and co-financed by the European Regional Development Fund, "A way of making Europe" from the European Union; and the agreement OA23/043 with Instituto Tecnológico y de Energías Renovables (ITER) to strengthen scientific and technological education, training, research, development and scientific innovation in genomics, epidemiological surveillance based on massive sequencing, personalized medicine, and biotechnology. Eva Suarez-Pajes was financially supported by Agencia Canaria de Investigación, Innovación y Sociedad de la Información de la Consejería de Economía, Conocimiento y Empleo y por el Fondo Social Europeo (FSE) Programa Operativo Integrado de Canarias 2014-2020, Eje 3 Tema Prioritario 74 (85%) (TESIS2022010042).

3 July 2025 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
SRSean C.S. Rivrud
Sean C.S. Rivrud
ÈHÈmese R.H. Heijkoop
Èmese R.H. Heijkoop
LHLisa Hulshof
Lisa Hulshof
NONiels C. Gritters van Den Oever
Niels C. Gritters van Den Oever
MWMik Wetterslev
Mik Wetterslev
RERuben J. Eck
Ruben J. Eck
Venous thromboembolism (VTE) is a serious complication of critical illness. The persistently high rates of VTE may be the result of thromboprophylaxis failure in critically ill patients at particularly high risk of VTE. A prognostic model may facilitate patient-specific interventions, ultimately lowering the incidence of VTE in critically ill patients. We aimed to develop and externally validate a prognostic model for VTE in critically ill patients: Predicting the Risk of Venous Thromboembolism in Critically Ill Patients model. The outcome was in-hospital VTE after intensive care unit admission. Model development was performed using multiple logistic regression with 14 established prognostic factors for VTE in critically ill patients. External validation was conducted in an independent cohort. Model performance was evaluated in terms of discrimination (C-statistic), calibration (integrated calibration index [ICI], E50, E90, Emax), and clinical utility (decision curve analysis [DCA]). The Predicting the Risk of Venous Thromboembolism in Critically Ill Patients (PROVE-IT) model was developed in 26 218 patients and externally validated in 1983 patients. Discrimination was acceptable with a C-statistic of 0.681 upon internal validation and 0.629 upon external validation. Calibration was excellent internally (ICI = 0.00231; E50 = 0.00184; E90 = 0.00313; Emax = 0.452) and good externally (ICI = 0.00664; E50 = 0.00447; E90 = 0.00131; Emax = 0.154). DCA suggested that the model may have clinical benefit over a range of risk thresholds (1.1%-4.7%), although not statistically significant. We developed and externally validated a prognostic model for in-hospital VTE in critically ill patients. Our model was well-calibrated upon external validation, although the discrimination was merely acceptable. Additionally, the model's clinical utility, assessed by DCA, is unclear, which precludes its recommendation for clinical implementation at this stage.

6 April 2025 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
SRSean C.S. Rivrud
Sean C.S. Rivrud
ÈHÈmese R.H. Heijkoop
Èmese R.H. Heijkoop
MSMarloes A.G. Holswilder–Olde Scholtenhuis
Marloes A.G. Holswilder–Olde Scholtenhuis
KMKarina Meijer
Karina Meijer
Pregnancy-related venous thromboembolism (VTE) is a major cause of maternal mortality and morbidity. While thromboprophylaxis can reduce the incidence of VTE, it may increase the risk of bleeding. Current guidelines recommend assessing VTE risk in pregnant women and administering low-molecular-weight heparin (LMWH) thromboprophylaxis to those at high risk. However, there is a paucity of evidence regarding the optimal dosing of postpartum LMWH thromboprophylaxis. To evaluate the safety and efficacy of fixed low-dose LMWH antepartum and weight-based high-dose LMWH (equivalent to weight-based therapeutic-dose LMWH) until 6 weeks postpartum in a prospective cohort of women at high risk for pregnancy-related VTE. From December 8, 2014, to November 9, 2023, we included patients at high risk for pregnancy-related VTE who required thromboprophylaxis during pregnancy and the puerperium. The primary safety outcome was the incidence of primary and secondary major postpartum hemorrhage. The secondary safety outcome was the incidence of primary and secondary postpartum clinically relevant nonmajor bleeding (CRNMB). The efficacy outcome was the incidence of VTE. Additional outcomes included treatment discontinuation and treatment modification. We found a 6.56% incidence of primary major postpartum hemorrhage, a 9.84% incidence of primary postpartum CRNMB, a 5.00% incidence of secondary postpartum CRNMB, a 3.33% incidence of VTE, a 16.1% incidence of treatment discontinuation, and a 30.6% incidence of treatment modification. When evaluating the optimal dose of thromboprophylaxis, the acceptable residual risk of VTE is debatable but should be considered in conjunction with the risks of adverse events, particularly bleeding and drug reactions, such as hypersensitivity skin reactions.